Sign up Australia
Proactive Investors - Run By Investors For Investors

MGC Pharmaceuticals bags $10M for medical cannabis growth

MGC’s cosmetics and dermatological product sales is growing.
MGC Pharmaceuticals bags $10M for medical cannabis growth
MGC is also assessing acquisition opportunities

MGC Pharmaceuticals (ASX:MXC) has closed an oversubscribed share placement after receiving commitments to raise $10 million via the issue of shares at $0.065 each.

MGC will use the funds to fast-track its growth objectives, including the research and development of pharmaceutical-grade cannabis based products.

In addition, the funds will be used to expand sales of the company’s cosmetics and dermatological product ranges.

MGC is also aggressively assessing acquisition opportunities in the Australian and international medicinal cannabis sector.

In January, MGC received approval in Europe for its cannabidiol based dermatological products for the relief of acne, psoriasis and seborrhoea skin conditions.

The development of a dermatologically tested cannabidiol skin care range is a key priority for MGC, given the significant commercial opportunity that such products represent globally.

In 2016, the company signed a distribution deal in California, U.S. for over 60,000 units of cannabidiol-based anti-aging cosmetics products with a contract value of about €1.2 million.

Carrying through a capital raise of $10 million is a substantial validation of the enormous potential of medical cannabis globally and MGC’s potential in this rapidly growing industry.

The company’s share price has increased by more than 80% since the start of 2017, last trading at $0.079.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full MXC profile View Profile

MGC Pharmaceuticals Ltd Timeline

Related Articles

syringe
June 21 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use